{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.45","value":"17.38"},{"groupId":"OG001","spread":"4.33","value":"17.81"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"189"},{"groupId":"OG001","value":"193"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.04","value":"0.61"},{"groupId":"OG001","spread":"3.14","value":"0.78"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"163"}],"units":"Participants"}],"title":"CFB at Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.85","value":"-0.60"},{"groupId":"OG001","spread":"4.42","value":"3.40"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"CFB at Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.08","value":"0.37"},{"groupId":"OG001","spread":"3.52","value":"0.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"152"}],"units":"Participants"}],"title":"CFB at Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.57","value":"0.53"},{"groupId":"OG001","spread":"4.03","value":"0.59"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"145"}],"units":"Participants"}],"title":"CFB at End of Induction Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.89","value":"0.66"},{"groupId":"OG001","spread":"3.83","value":"0.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"138"}],"units":"Participants"}],"title":"CFB at Follow-up Month 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.54","value":"1.34"},{"groupId":"OG001","spread":"3.51","value":"0.95"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"124"}],"units":"Participants"}],"title":"CFB at Follow-up Month 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.57","value":"0.89"},{"groupId":"OG001","spread":"3.44","value":"0.96"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"116"}],"units":"Participants"}],"title":"CFB at Follow-up Month 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.35","value":"0.26"},{"groupId":"OG001","spread":"3.34","value":"0.97"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"108"}],"units":"Participants"}],"title":"CFB at Follow-up Month 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.31","value":"0.69"},{"groupId":"OG001","spread":"3.23","value":"1.32"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"94"}],"units":"Participants"}],"title":"CFB at Follow-up Month 10"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.88","value":"-0.07"},{"groupId":"OG001","spread":"3.29","value":"0.95"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"93"}],"units":"Participants"}],"title":"CFB at Follow-up Month 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.22","value":"0.46"},{"groupId":"OG001","spread":"3.82","value":"1.07"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"89"}],"units":"Participants"}],"title":"CFB at Follow-up Month 14"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.87","value":"0.13"},{"groupId":"OG001","spread":"3.69","value":"1.04"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"86"}],"units":"Participants"}],"title":"CFB at Follow-up Month 16"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.36","value":"0.42"},{"groupId":"OG001","spread":"3.38","value":"1.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"79"}],"units":"Participants"}],"title":"CFB at Follow-up Month 18"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.90","value":"-0.43"},{"groupId":"OG001","spread":"4.28","value":"0.94"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"76"}],"units":"Participants"}],"title":"CFB at Follow-up Month 20"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.81","value":"0.18"},{"groupId":"OG001","spread":"3.79","value":"0.97"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"74"}],"units":"Participants"}],"title":"CFB at Follow-up Month 22"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.20","value":"0.06"},{"groupId":"OG001","spread":"3.78","value":"1.12"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"71"}],"units":"Participants"}],"title":"CFB at Follow-up Month 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.77","value":"0.38"},{"groupId":"OG001","spread":"4.37","value":"0.34"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"111"}],"units":"Participants"}],"title":"CFB at Final Follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.26","value":"-0.44"},{"groupId":"OG001","spread":"3.99","value":"0.39"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"63"}],"units":"Participants"}],"title":"CFB at Extension Follow-up Month 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.80","value":"-0.08"},{"groupId":"OG001","spread":"3.85","value":"0.75"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"50"}],"units":"Participants"}],"title":"CFB at Extension Follow-up Month 18"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.16","value":"1.04"},{"groupId":"OG001","spread":"4.36","value":"0.97"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"title":"CFB at Extension Follow-up Month 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"189"},{"groupId":"OG001","value":"193"}],"units":"Participants"}],"description":"The FACT-Lym measures 5 sub-scales which includes 42 items; responses to each item range from 0, \"Not at all\" to 4, \"Very much\". Total score ranges from 0-168. Emotional Well-being sub-scale includes 6 items measured on 0-4 point scale. The total score for emotional well-being sub-scale is sum of each 6 items (range: 0-24). Higher scores indicate a better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).","dispersionType":"Standard Deviation","groups":[{"description":"Participants received Bendamustine 120 mg/m\\^2 IV infusion on Days 1 and 2 of each 28-day cycle for up to six cycles.","id":"OG000","title":"Bendamustine Alone"},{"description":"Induction phase: Participants received Bendamustine 90 mg/m\\^2 IV on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of Cycles 2-6 (28-day cycles) for the first 10 participants and on Days 1 and 2 of each 28-day cycle for Cycles 1-6 for remaining participants. Participants also received obinutuzumab 1000 mg IV infusion on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2-6. Maintenance phase: Participants with CR, PR or SD then received obinutuzumab 1000 mg IV infusion every 2 months until disease progression or for up to 2 years (whichever occurred first).","id":"OG001","title":"Obinutuzumab + Bendamustine"}],"paramType":"MEAN","populationDescription":"ITT population. Here, number of participants analyzed signified those participants who were evaluable for this outcome and \"n\" signified those participants who were evaluable for a specified time point.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6, 18 and 24","title":"CFB in FACT-Lym-Emotional Well-Being Sub-scale Score","type":"SECONDARY","unitOfMeasure":"units on a scale"}